Mar 14, 2026

Why EudraVigilance and E2B(R3) Skills Still Matter in 2026

It is easy to assume that modern pharmacovigilance careers are moving entirely toward AI, automation, and advanced analytics. But EMA’s 2026 EudraVigilance training agenda is a helpful reminder that foundational reporting skills still matter deeply. EMA’s hands-on training course says participants should be able to apply the ISO/ICH E2B(R3) format and rules to spontaneous and follow-up reports, amendment and nullification reports, literature cases, parent-child cases, and reports from interventional and non-interventional studies.

That is not niche knowledge. It sits at the heart of operational pharmacovigilance in the EU environment. EMA also states that EudraVigilance is the system for managing and analysing information on suspected adverse reactions to medicines authorised or being studied in the European Economic Area, and that the agency operates the system on behalf of the EU medicines regulatory network.

For career-minded professionals, this means that EudraVigilance literacy is still highly relevant. Being able to navigate EV processes, understand ICSR structures, apply E2B(R3) rules, and work accurately across different case types is not outdated. It is part of the infrastructure of real pharmacovigilance work.

There is a broader point here too. In many industries, foundational skills lose value when automation expands. In pharmacovigilance, the opposite is often true. Automation can increase the need for people who understand the underlying structure of the work. If a professional does not understand what a correctly formed safety report looks like, what amendment and nullification mean, or how reporting obligations differ across contexts, they may struggle to supervise or evaluate digital tools effectively. That is an inference, but it fits the logic of regulated automation.

So while AI and digital transformation deserve attention, PV professionals should not neglect the core reporting competencies that make the field function. In 2026, the most resilient careers may belong to people who combine foundational reporting literacy with modern digital awareness.

Why this matters for PV professionals
EMA’s 2026 training agenda shows that EudraVigilance and E2B(R3) are still part of the profession’s core. In a changing market, strong fundamentals remain a genuine career asset.

Related Posts

Comments

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Stay Ahead of Pharmacovigilance News

Subscribe to PV Watch Daily and get the latest drug safety updates, regulatory developments, safety signals, industry alerts, and expert insights delivered straight to your inbox.